Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05996627 · ClinicalTrials.gov registry record · Phase 2

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
82
Enrollment target
4
Study locations

NCT05996627 is a Phase 2 study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 82 participants, below the 114-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (28% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05996627, a Phase 2 study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
82 participants
Enrollment target
4
Study locations

Study Summary

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • PROCEDURE Biospecimen Collection
  • DRUG Belumosudil
  • OTHER Electronic Health Record Review
  • DRUG Placebo Administration

Study Locations (4)

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2023-12-06
Est. Completion 2028-11-30
Phase Phase 2

Sponsor

Fred Hutchinson Cancer Center

483 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05996627

The ClinicalTrials.gov registry entry for NCT05996627 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (28% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT05996627 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT05996627 about?

NCT05996627 is a clinical study titled "Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease". This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibi...

What is the current status of trial NCT05996627?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2023-12-06. Estimated completion is 2028-11-30.

What conditions does trial NCT05996627 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT05996627?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Belumosudil (DRUG), Electronic Health Record Review (OTHER), Placebo Administration (DRUG).

Who is sponsoring clinical trial NCT05996627?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05996627 being conducted?

This trial has 4 study locations across Florida, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Graft Versus Host Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.